抗VEGF-B抗体片段诱导大鼠角膜已存在血管消退
研究测试了特异性针对血管内皮生长因子-B(VEGF-B)的抗体片段在Sprague Dawley大鼠角膜中对新生和已建立血管的消退能力。单链可变区抗体片段(scFv)经表面等离子共振确认可结合大鼠、小鼠和人VEGF-B。局部滴用抗VEGF-B scFv单独治疗未显著消退角膜血管(P > 0.05),而结膜下注射和联合治疗分别使14天已建立角膜血管面积减少25%(P = 0.04)和37%(P < 0.001),且在治疗角膜的血管内皮细胞中检测到cleaved caspase-3。
要点
- 局部滴用抗VEGF-B scFv单独治疗未显著消退大鼠角膜血管(P > 0.05)。
- 结膜下注射和联合治疗使14天已建立角膜血管面积分别减少25%(P = 0.04)和37%(P < 0.001)。
- 抗VEGF-B scFv治疗角膜的血管内皮细胞中检测到cleaved caspase-3。
核心结论
- 抗VEGF-B scFv显著消退大鼠已建立但未消退新生角膜血管。
研究设计与样本
- 在雄性和雌性远交系Sprague Dawley大鼠中,行单侧角膜表层烧灼后,评估抗VEGF-B scFv对发展中及已建立角膜血管的作用。
- 分组包括未治疗组、对照scFv治疗组或抗VEGF-B scFv治疗组,每组6至22只大鼠。
- 治疗为5 μL scFv(1 mg/mL)局部滴用每天五次共14天,或两次结膜下注射(每次50 μg scFv,间隔7天),或局部联合结膜下治疗。
- 角膜血管面积在苏木精染色的角膜铺片上量化,组间比较采用Mann-Whitney U检验,并进行Bonferroni校正。
- 进行cleaved caspase-3免疫组织化学检测。
主要发现
- 局部抗VEGF-B scFv治疗单独未显著消退角膜血管(P > 0.05)。
- 结膜下注射和联合治疗使14天已建立角膜血管面积分别减少25%(P = 0.04)和37%(P < 0.001),与未治疗对照组相比。
- 在抗VEGF-B scFv治疗角膜的血管内皮细胞中检测到cleaved caspase-3。
- 在scFv治疗大鼠中,角膜内皮细胞功能维持至治疗后12周,且眨眼反射正常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We tested the ability of an antibody fragment with specificity for vascular endothelial growth factor-B (VEGF-B) to regress nascent and established corneal blood vessels in the rat. METHODS: A single chain variable antibody fragment (scFv) with specificity for VEGF-B was engineered from the 2H10 hybridoma. Binding to rat, mouse, and human VEGF-B was confirmed by surface plasmon resonance. Activity of the anti-VEGF-B scFv on developing and established corneal blood vessels was assessed following unilateral superficial cautery in male and female outbred Sprague Dawley rats. Groups (untreated, control scFv-treated, or anti-VEGF-B scFv-treated) comprised 6 to 22 rats. Treatment consisted of 5 μL scFv, 1 mg/mL, applied topically five times per day for 14 days, or two subconjunctival injections, 50 μg scFv each, applied 7 days apart, or combined topical and subconjunctival treatment. Corneal vessel area was quantified on hematoxylin-stained corneal flat-mounts, and groups were compared using the Mann-Whitney U test, with post hoc Bonferroni correction. Immunohistochemistry for cleaved caspase-3 was performed. RESULTS: Topical anti-VEGF-B scFv therapy alone did not regress corneal blood vessels significantly (P > 0.05). Subconjunctival injection and combined treatment regressed 14-day established corneal blood vessels (25% reduction in vessel area [P = 0.04] and 37% reduction in vessel area [P < 0.001], respectively, compared to results in untreated controls). Cleaved caspase-3 was identified in vascular endothelial cells of anti-VEGF-B scFv-treated corneas. In scFv-treated rats, corneal endothelial cell function was maintained to 12 weeks after treatment and a normal blink reflex was present. CONCLUSIONS: The anti-VEGF-B scFv significantly regressed established but not developing corneal blood vessels in rats.
引用
- Irani YD, Scotney PD, Klebe S, et al. An Anti-VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea. Invest Ophthalmol Vis Sci. 2017. PMID: 28692735. doi:10.1167/iovs.16-21343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。